GSK plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GSK research report →
About the company
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally.
- CEO
- Luke Victor Miels
- IPO
- 1980
- Employees
- 68,629
- HQ
- Brentford, GB
Price Chart
- Market Cap
- $104.67B
- P/E
- 13.46
- P/S
- 2.38
- P/B
- 4.39
- EV/EBITDA
- 8.11
- Div Yield
- 3.44%
- Gross Margin
- 72.74%
- Op Margin
- 22.34%
- Net Margin
- 17.78%
- ROE
- 35.78%
- ROIC
- 13.76%
- Revenue
- $32.67B · 4.11%
- Net Income
- $5.72B · 121.98%
- EPS
- $5.64 · 347.62%
- Op Income
- $8.34B
- FCF YoY
- 63.06%
- 52W High
- $61.70
- 52W Low
- $35.45
- 50D MA
- $52.87
- 200D MA
- $49.96
- Beta
- 0.29
- Avg Volume
- 4.07M
Get TickerSpark's AI analysis on GSK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our GSK coverage
Recent articles, reports, and earnings notes.
GSK (GSK): Specialty Medicines Drive a Re-Rating
GSK is evolving from a mature pharma cash generator into a more balanced growth story, with Specialty Medicines driving faster growth and margins improving. The stock still looks reasonably valued versus its earnings power and pipeline.
GSK plc (GSK) drops 6.4% After Q1 Beat
GSK plc (GSK) fell after Q1 2026 results despite beating sales and profit forecasts. Investors focused on the quality of the beat, with much of the upside tied to legal settlement provisions and mixed segment trends across vaccines and medicines.
Want a deeper read on GSK?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.